Dengue
155
17
23
94
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
32 trials with published results (21%)
Research Maturity
94 completed trials (61% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.8%
9 terminated out of 155 trials
91.3%
+4.7% vs benchmark
8%
12 trials in Phase 3/4
34%
32 of 94 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 94 completed trials
Clinical Trials (155)
Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers
Adaptive Dengue Antiviral Platform Trial
Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection
Efficacy and Safety of Indoor Residual Spray for Dengue Vector Control
Immune Responses to Dengue and Sepsis
Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults
Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso
Validation of a CDSA Strategy to Reduce Antibiotic Prescription in Senegal
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)
Investigating and Modelling the Natural History of Dengue in Hospitalised Patients to Improve Future Research
Gut Leakage' in Dengue
Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)
Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)
Efficacy and Safety of Carica Papaya in Dengue Fever: A Randomised Clinical Trial
Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients
Improving Disease Prevention Strategies by Integrating Socio-spatial Characterization of Human Mobility
Therapeutics for Moderate and Severe Dengue
Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam